Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cet article présente les recommandations d'une société savante européenne sur le diagnostic d'un lymphome hodgkinien, la prise en charge thérapeutique des patients et leur suivi
incidence : The crude incidence of Hodgkin's lymphoma (HL) in the European Union is 2.3 and the mortality is 0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected; however, a second incidence peak is seen in individuals aged 55 and older. Slightly more men than women are diagnosed with HL. Histologically, classical HL (cHL) accounting for ∼95% of all HL cases is distinguished from nodular lymphocyte-predominant HL (NLPHL) representing ∼5% of all HL cases. diagnosis : Pathological diagnosis should be made according to the World Health Organization (WHO) classification from a sufficiently large surgical specimen or excisional lymph node biopsy to provide enough material for fresh frozen and formalin-fixed samples. In cHL, the presence of Hodgkin and Reed–Sternberg (HRS) cells is disease-defining while the detection of lymphocyte predominant (LP) cells is required for the diagnosis of NLPHL. The immunophenotype of the malignant cells in cHL and NLPHL differs significantly. In contrast to HRS cells that stain consistently positive for CD30 and CD15, occasionally positive for CD20 and negative for CD45, LP cells are characterised by the expression of CD20 and CD45 but they lack CD15 and CD30.
Annals of Oncology 2014